All Stories

  1. Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases
  2. Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study
  3. Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study
  4. Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B‐Cell Depletion
  5. Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study
  6. Temporal trends in the incidence and prevalence of multiple sclerosis in Sweden 2001-2021
  7. Divergence of C4A and C4B in first-episode psychosis: Insights from CSF and plasma immune profiling
  8. Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
  9. Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study
  10. Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
  11. Changes in Multiple Sclerosis Clinical Care and Outcomes During the COVID‐19 Era: A Population‐Wide Study
  12. Correlates of patient reported quality of life in a large multiple sclerosis cohort encompassing the COVID-19 pandemic period
  13. A human pan-disease blood atlas of the circulating proteome
  14. Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis
  15. Beneficial impact of physical activity on multiple sclerosis disability progression
  16. Cardiovascular protein profiling in patients with first-episode psychosis
  17. Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
  18. Fluid biomarkers of chronic traumatic brain injury
  19. Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis
  20. Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study
  21. Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy
  22. Neurofilaments as biomarkers in neurological disorders — towards clinical application
  23. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study
  24. Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study
  25. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment
  26. COVID-19–Related Enhancement for the COMBAT-MS Study
  27. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
  28. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
  29. Multiple Sclerosis, Disease-Modifying Therapies, and Infections
  30. Systemic Capillary Leak Syndrome With Cerebral Involvement in a C9orf72 Expansion Carrier
  31. Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis
  32. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
  33. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic
  34. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
  35. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression
  36. Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
  37. The Karolinska NeuroCOVID study protocol: Neurocognitive impairment, biomarkers and advanced imaging in critical care survivors
  38. Demyelinating events following anti‐tumor necrosis factor alpha therapy: Rare but challenging to treat
  39. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
  40. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
  41. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
  42. Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis
  43. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
  44. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
  45. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
  46. Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis
  47. Association of Infectious Mononucleosis in Childhood and Adolescence With Risk for a Subsequent Multiple Sclerosis Diagnosis Among Siblings
  48. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort
  49. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
  50. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
  51. Risk of depression in multiple sclerosis across disease-modifying therapies
  52. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study
  53. Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury
  54. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance
  55. Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology
  56. Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity
  57. Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis
  58. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
  59. Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood–brain barrier disruption and outcome prediction following severe traumatic brain injury: a prospective, observational study
  60. Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis
  61. Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis
  62. Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects
  63. Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury
  64. Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
  65. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study
  66. Current and emerging disease modulatory therapies and treatment targets for multiple sclerosis
  67. Effect of Vitamin D on Experimental Autoimmune Neuroinflammation Is Dependent on Haplotypes Comprising Naturally Occurring Allelic Variants of CIITA (Mhc2ta)
  68. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
  69. Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
  70. Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus
  71. Infections in patients with multiple sclerosis: A national cohort study in Sweden
  72. A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
  73. Is the treatment of myasthenia gravis improving?
  74. The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis
  75. Neurological manifestations of coronavirus infections – a systematic review
  76. Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis
  77. The genetic architecture of human brainstem structures and their involvement in common brain disorders
  78. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
  79. Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden
  80. Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate
  81. Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS
  82. Rituximab, MS, and pregnancy
  83. Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis
  84. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
  85. CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
  86. Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas/Casp8/Bid-axis
  87. Inflammation-related plasma and CSF biomarkers for multiple sclerosis
  88. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
  89. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
  90. Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
  91. A Novel, Robust Method for Quantification of Multiple Kynurenine Pathway Metabolites in the Cerebrospinal Fluid
  92. Blood neurofilament light levels segregate treatment effects in multiple sclerosis
  93. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
  94. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
  95. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
  96. Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease
  97. Quantification of Plasma Kynurenine Metabolites Following One Bout of Sprint Interval Exercise
  98. MRI‐Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis
  99. Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis
  100. Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome
  101. A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury
  102. Epilepsy in systemic lupus erythematosus: prevalence and risk factors
  103. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
  104. Common brain disorders are associated with heritable patterns of apparent aging of the brain
  105. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
  106. Different epigenetic clocks reflect distinct pathophysiological features of multiple sclerosis
  107. Incidence of osmotic demyelination syndrome in Sweden: A nationwide study
  108. Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients
  109. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
  110. Increased peripheral levels of TARC/CCL17 in first episode psychosis patients
  111. GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
  112. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
  113. Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk
  114. Rituximab treatment for multiple sclerosis
  115. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
  116. Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis
  117. Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury
  118. Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression
  119. The association between multiple sclerosis and pain medications: Erratum.
  120. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
  121. Validation of the Swedish Multiple Sclerosis Register
  122. B cell alterations during BAFF inhibition with belimumab in SLE
  123. Morvan’s syndrome treated successfully with rituximab and lacosamide
  124. Author Correction: Multiple sclerosis
  125. Multiple sclerosis
  126. International consensus on quality standards for brain health-focused care in multiple sclerosis
  127. The association between multiple sclerosis and pain medications
  128. miR-31 regulates energy metabolism and is suppressed in T cells from patients with Sjögren's syndrome
  129. Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients
  130. Identification of MS-specific serum miRNAs in an international multicenter study
  131. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
  132. Neurofilaments as biomarkers in neurological disorders
  133. Increased number of monocytes and plasma levels ofMCP‐1 andYKL‐40 in first‐episode psychosis
  134. Polygenic link between blood lipids and amyotrophic lateral sclerosis
  135. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis
  136. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
  137. Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers
  138. Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures
  139. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes
  140. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
  141. Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients
  142. The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis
  143. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
  144. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
  145. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
  146. Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis
  147. Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis
  148. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
  149. Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes
  150. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
  151. A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis
  152. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry
  153. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
  154. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
  155. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
  156. CSF GABA is reduced in first-episode psychosis and associates to symptom severity
  157. Multiple Sclerosis—A Tuning Fork Still Required
  158. Population-based incidence and clinical characteristics of idiopathic intracranial hypertension
  159. Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution
  160. Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report
  161. Effects ofC2tagenetic polymorphisms on MHC class II expression and autoimmune diseases
  162. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
  163. Rituximab in multiple sclerosis
  164. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study
  165. Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Toll‐like Receptor Stimulation in Peripheral Monocytes
  166. NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk
  167. Reply
  168. Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions
  169. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
  170. Absence of systemic oxidative stress and increased CSF prostaglandin F 2α in progressive MS
  171. T-cell activation and HLA-regulated response to smoking in the deep airways of patients with multiple sclerosis
  172. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
  173. Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
  174. Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function
  175. No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination
  176. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
  177. High-intensity resistance training in multiple sclerosis — An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition
  178. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
  179. Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
  180. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms
  181. Rituximab in paediatric onset multiple sclerosis: a case series
  182. Complement receptor 2 is up regulated in the spinal cord following nerve root injury and modulates the spinal cord response
  183. MicroRNAs as promising novel biomarkers and potential drug targets for inflammatory neurological diseases
  184. Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light
  185. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis
  186. Is a Cancer Diagnosis Associated with Subsequent Risk of Transient Global Amnesia?
  187. Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis
  188. P300 amplitude and response speed relate to preserved cognitive function in relapsing–remitting multiple sclerosis
  189. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
  190. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
  191. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
  192. Risk factors for amyotrophic lateral sclerosis
  193. Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations
  194. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis
  195. The autoimmune spectrum of myasthenia gravis: a Swedish population‐based study
  196. High interleukin-6 and impulsivity: determining the role of endophenotypes in attempted suicide
  197. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells
  198. High Glutathione-S-transferase 4 alpha expression promotes nerve cell survival in neurodegenerative disorders
  199. Genetic study of Pandemrix-associated narcolepsy
  200. Methylome characterization of CD4+ T cells in multiple sclerosis — Establishing a role for miR-21 in autoimmune disease
  201. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party
  202. Age-dependent effects on the treatment response of natalizumab in MS patients
  203. A changing treatment landscape for multiple sclerosis: challenges and opportunities
  204. Unbiased Expression Mapping Identifies a Link between the Complement and Cholinergic Systems in the Rat Central Nervous System
  205. Variability in the CIITA gene interacts with HLA in multiple sclerosis
  206. Phenotypes and Predictors of Pain Following Traumatic Spinal Cord Injury: A Prospective Study
  207. Variability in C-Type Lectin Receptors Regulates Neuropathic Pain-Like Behavior after Peripheral Nerve Injury
  208. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
  209. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
  210. Regulated Extracellular Choline Acetyltransferase Activity— The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway
  211. Genetic variability in the rat Aplec C-type lectin gene cluster regulates lymphocyte trafficking and motor neuron survival after traumatic nerve root injury
  212. Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
  213. Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
  214. Naturally Occurring Variation in the Glutathione-S-Transferase 4 Gene Determines Neurodegeneration After Traumatic Brain Injury
  215. Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
  216. The DQB1*03:02 HLA haplotype is associated with increased risk of chronic pain after inguinal hernia surgery and lumbar disc herniation
  217. Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis
  218. Strain influences on inflammatory pathway activation, cell infiltration and complement cascade after traumatic brain injury in the rat
  219. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
  220. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13
  221. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters
  222. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
  223. Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes
  224. Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08
  225. The Calcitonin Receptor Gene Is a Candidate for Regulation of Susceptibility to Herpes simplex Type 1 Neuronal Infection Leading to Encephalitis in Rat
  226. Genetic and sex influence on neuropathic pain‐like behaviour after spinal cord injury in the rat
  227. Unmet medical needs with current standard treatments
  228. iNOS-mediated secondary inflammatory response differs between rat strains following experimental brain contusion
  229. Naturally Occurring Genetic Variability in Expression of Gsta4 is Associated with Differential Survival of Axotomized Rat Motoneurons
  230. Inflammatory and haemostatic markers in idiopathic intracranial hypertension
  231. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
  232. Concomitant autoimmunity in myasthenia gravis — Lack of association with IgA deficiency
  233. Both MHC and non-MHC genes regulate inflammation and T-cell response after traumatic brain injury
  234. The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis
  235. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
  236. High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction?
  237. Profiling of CD4+ T Cells with Epigenetic Immune Lineage Analysis
  238. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
  239. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
  240. Influence of Perineurial Cells and Toll-Like Receptors 2 and 9 on Herpes simplex Type 1 Entry to the Central Nervous System in Rat Encephalitis
  241. Genetic regulation of microglia activation, complement expression, and neurodegeneration in a rat model of traumatic brain injury
  242. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study
  243. Genetic aspects in TBI
  244. Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta
  245. Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury
  246. Fine Mapping of Gene Regions Regulating Neurodegeneration
  247. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment‐sensitive biomarkers
  248. Inflammation and susceptibility to neurodegeneration: The use of unbiased genetics to decipher critical regulatory pathways
  249. Contrasting genetic effects of major histocompatibility complex on ischemic peripheral nerve and spinal cord injury in female rats
  250. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
  251. Both MHC and non-MHC genes regulate development of experimental neuropathic pain in rats
  252. Genetic analysis of neuropathic pain-like behavior following peripheral nerve injury suggests a role of the major histocompatibility complex in development of allodynia
  253. Vra4 Congenic Rats with Allelic Differences in the Class II Transactivator Gene Display Altered Susceptibility to Experimental Autoimmune Encephalomyelitis
  254. Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis
  255. The axon reaction: Identifying the genes that make a difference
  256. Recovery from spinal cord injury differs between rat strains in a major histocompatibility complex-independent manner
  257. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
  258. Decreased Expression of VEGF‐A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis
  259. Genetics of autoimmune neuroinflammation
  260. Decreased Expression of VEGF‐A in Rat Experimental Autoimmune Encephalomyelitis and in Cerebrospinal Fluid Mononuclear Cells from Patients with Multiple Sclerosis
  261. Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes
  262. Differential Expression of the Chemokine Receptors CX3CR1 and CCR1 by Microglia and Macrophages in Myelin-Oligodendrocyte-Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis
  263. Genetic Regulation of Nerve Avulsion-Induced Spinal Cord Inflammation
  264. Inflammation and neurodegeneration
  265. Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems
  266. Genetic dissection of neurodegeneration and CNS inflammation
  267. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
  268. A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy
  269. T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis
  270. Prior poliomyelitis—IvIg treatment reduces proinflammatory cytokine production
  271. Increased Brain‐Derived Neurotrophic Factor Expression in White Blood Cells of Relapsing–Remitting Multiple Sclerosis Patients
  272. Harm or heal – divergent effects of autoimmune neuroinflammation?
  273. Properties of motoneurons underlying their regenerative capacity after axon lesions in the ventral funiculus or at the surface of the spinal cord
  274. Facial nerve lesion response; strain differences but no involvement of IFN-γ, STAT4 or STAT6
  275. Upregulation of VEGF-A Without Angiogenesis in a Mouse Model of Dilated Cardiomyopathy Caused by Mitochondrial Dysfunction
  276. Differential Expression of Neurotrophic Factors and Inflammatory Cytokines by Myelin Basic Protein‐Specific and Other Recruited T Cells Infiltrating the Central Nervous System during Experimental Autoimmune Encephalomyelitis
  277. Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse
  278. Neuroinflammation in the rat - CNS cells and their role in the regulation of immune reactions
  279. Menin Interacts Directly with the Homeobox-Containing Protein Pem
  280. Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non‐MHC genes in congenic inbred rat strains
  281. Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non-MHC genes in congenic inbred rat strains
  282. Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration
  283. Neuroprotection by Encephalomyelitis: Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNS-Infiltrating T and Natural Killer Cells
  284. Genetics of rat neuroinflammation
  285. Molecular characterization of human and murine C11orf5, a new member of the FAUNA gene cluster
  286. Differential regulation of trophic factor receptor mRNAs in spinal motoneurons after sciatic nerve transection and ventral root avulsion in the rat
  287. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis
  288. Regulation of laminin-associated integrin subunit mRNAs in rat spinal motoneurons during postnatal development and after axonal injury
  289. Expression of nonclassical MHC class I (RT1-U) in certain neuronal populations of the central nervous system
  290. Expression of MHC class I heavy chain and β2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons
  291. Non-MHC gene regulation of nerve root injury induced spinal cord inflammation and neuron death
  292. Restricted Expression Pattern ofvegf-din the Adult and Fetal Mouse: High Expression in the Embryonic Lung
  293. Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries
  294. Expression of insulin‐like growth factors and corresponding binding proteins (IGFBP 1–6) in rat spinal cord and peripheral nerve after axonal injuries
  295. Characterization of the mouse Men1 gene and its expression during development
  296. Characterization of the human synaptogyrin gene family
  297. Expression and chromosomal localization of the Requiem gene
  298. Expression of theBCL6Gene in the Pre- and Postnatal Mouse
  299. A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse
  300. Mapping of the human Ca2+ channel β4 subunit to 2q22-23 and its expression in developing mouse
  301. Changes in the mRNA expression pattern, with special reference to calcitonin gene-related peptide, after axonal injuries in rat motoneurons depends on age and type of injury
  302. VAMP‐1 and VAMP‐2 gene expression in rat spinal motoneurones: differential regulation after neuronal injury
  303. Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas
  304. Sequence and Expression of the Mouse Homologue to Human Phospholipase C β3 Neighboring Gene
  305. Differential subcellular localization of SNAP-25a and SNAP-25b RNA transcripts in spinal motoneurons and plasticity in expression after nerve injury
  306. Expression of the VEGF-Related Factor Gene in Pre- and Postnatal Mouse
  307. GDNF mRNA in Schwann cells and DRG satellite cells after chronic sciatic nerve injury
  308. Expression of the phosphoinositide-specific phospholipase Cβ3 gene in the rat
  309. Differential effects of combined trk receptor mutations on dorsal root ganglion and inner ear sensory neurons
  310. Prominent Expression of bFGF in Dorsal Root Ganglia after Axotomy
  311. Expression of NMDA Receptor mRNAs in Rat Motoneurons is Down-regulated after Axotomy
  312. Increase in α-CGRP and GAP-43 in aged motoneurons: A study of peptides, growth factors, and ChAT mRNA in the lumbar spinal cord of senescent rats with symptoms of hindlimb incapacities
  313. Fibroblast Growth Factors Regulate Calcitonin Gene-related Peptide mRNA Expression in Rat Motoneurons after Lesion and in Culture
  314. Adhesive/Repulsive Properties in the Injured Spinal Cord: Relation to Myelin Phagocytosis by Invading Macrophages
  315. Increased trkB mRNA expression by axotomized motoneurones
  316. trkC-like Immunoreactivity in the Primate Descending Serotoninergic System
  317. The peptidergic motoneurone
  318. Calcitonin Gene-Related Peptide in the Brain, Spinal Cord, and Some Peripheral Systems
  319. Calcitonin Gene-related Peptide (CGRP)-like Immunoreactivity and CGRP mRNA in Rat Spinal Cord Motoneurons after Different Types of Lesions